3Richardson P,Anderson K. Thalidomide and dexamethasone:A new standard of care for initial therapy in multiple myeloma[J].Journal of Clinical Oncology,2006,(03):334-336.
2BLADE J, SAMSON D, REECE D, et al. Criteria for evaluating disease response and progression in patients with multiplemyeloma treated by high dose therapy and hemopoietic stem cell transplantation. Myeloma Subcommittee of the EMBT. European Group for Blood and Marrow Transplant [ J ]. Br J Haematol, 1998,102 (5) : 1115-1123.
3FIELD-SMITH A, MORGAN G J, DAVIES F E. Bortezomib (Veleade^TM) in the treatment of multiple myeloma[J]. Ther Clin Risk Manag, 2006, 2 ( 3 ) :271-279.
4ROODMAN G D. Bone building with bortezomib [ J ]. J Clin Invest, 2008, 118(2) :462-464.
5SMITH M R. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence [ J ]. Cancer Treat Rev, 2005, 31(3) :19-25.
6YEH H S, BERENSON J R. Treatment for myeloma bone disease [ J ]. Clin Cancer Res,2006,12 (20) :6279-6284.
7JAGANNATH S, BRIAN D, WOLF JL, et al. A phase 2 study of bortezomib as first-line therapy in patients with multiple myeloma [J]. Blood, 2004,104 : Abstract 333.
8RICHARDSON P G, CHANAN-KHAN A, SCHLOSSMAN R L, et al. Phase Ⅱ trial of single agent bortezomib in patients with previously untreated multiple myeloma [ J ]. Blood, 2004, 104 : Abstract 336.
9WU K L, VAN WIERINGEN W, VELLENGA E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice[ J], Haematologica, 2005, 90 (7) :996-997.
10RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
